Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Mineralization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCPK:GNMSF)

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Benzinga.com  May 1, 2018

Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

PR Newswire March 26, 2018

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 22, 2018

PR Newswire March 21, 2018

Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018

PR Newswire March 21, 2018

Genmab 2017 Annual Report

GlobeNewswire February 21, 2018

Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)

GlobeNewswire January 23, 2018

Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets

GlobeNewswire January 22, 2018

U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma

GlobeNewswire January 19, 2018

Major Shareholder Announcement

GlobeNewswire January 9, 2018
View More News ››

Opinion & Analysis (OTCPK:GNMSF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCPK:GNMSF)

TEPKINLY&#xAE; (epcoritamab) Receives Second European Commis

Just In: $GNMSF TEPKINLY&#xAE; (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed...
whytestocks - August 19, 2024

Diamond in the rough

Been buying in mid-19's. Went to a lecture at BWH on their new drug for myeloma. They said it was a miracle drug. Awesome stock. No...
MORGUE1 - September 11, 2014
View more Bullboard ››

Spirit Blockchain Capital Inc.

Spirit Blockchain Capital Inc.

Spirit Blockchain Capital Inc. is an investment company focused on blockchain industry. Through its operational business line ...
View More »